#United States #Class Action #San Francisco #Securities Fraud #ADMA Biologics

ADMA Biologics and the Class Action Lawsuit

Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) have been alerted to a significant class action lawsuit focused on alleged securities fraud. This legal action, spearheaded by the firm Hagens Berman, comes amid accusations of misrepresentation regarding the company's financial status, revenue recognition, inventory management, and business operations.

Background of the Lawsuit

The lawsuit, which covers a class period from August 9, 2024, to March 25, 2026, outlines claims that the leadership at ADMA Biologics engaged in misleading practices that inflated the stock's value artificially. Specific allegations include:

• - Failure to disclose undisclosed related party transactions;
• - Using a practice referred to as channel stuffing to exaggerate revenue reports;
• - Lack of adequate internal controls, leading to misstatements about the company’s operations and future prospects.

This legal drama primarily revolves around claims suggesting that statements made by ADMA management were not only materially false but also lacked a reasonable basis at crucial times, ultimately harming investors.

Key Events Leading to the Fraud Allegations

The suit outlines several corrective disclosure events that led to a dramatic decline in ADMA's stock price, wiping out millions in value for shareholders. Here’s a timeline of critical events:

• - March 24, 2026: A short-seller report from Culper Research unveiled serious allegations regarding channel stuffing and undisclosed transactions with a related party, Genesis BioPharma, resulting in a staggering sell-off. The stock price plummeted by 31.6% cumulatively across two days, with significant drops on both March 24 (down 16.6%) and March 25 (down 15%).
• - March 26, 2026: ADMA issued a press release in response to the revelations but faced further decline after a stock rating downgrade by Cantor Fitzgerald, leading to a 13.9% drop in stock value.

Hagens Berman's Investigation

Reed Kathrein, a partner at Hagens Berman, stated, “We’re investigating whether ADMA made false and misleading statements to investors, concealing the true nature of its distribution channels and financial health.” This investigation is critical for ensuring accountability and transparency regarding ADMA's alleged actions.

What Affected Investors Can Do

For those who have suffered substantial losses in ADMA Biologics stock, it is imperative to take action. Hagens Berman encourages affected investors to step forward and share their experiences or any information that could assist in the ongoing investigation.

The firm also outlines the avenues for whistleblowers, especially those privy to non-public information regarding the company. Given the newly expanded SEC Whistleblower program, individuals providing original information that leads to a successful recovery could receive rewards up to 30% of the total recovery amount.

For more information or to submit a claim, stakeholders can visit Hagens Berman's website or contact them directly.

Conclusion

The developments surrounding ADMA Biologics serve as a reminder of the risks associated with investing in publicly traded companies, particularly concerning the accuracy of financial disclosures and corporate governance. As the case progresses, the implications for both ADMA and its investors will undoubtedly unfold, showcasing the vital role legal scrutiny plays in maintaining market integrity.